APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Diabetes Treatment Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global GLP-1 Diabetes Treatment Drugs Industry Growth and Trends Forecast to 2032

23 December 2025113 pages

Choose your research edition.

Industry ResearchGLP-1 Diabetes Treatment Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Diabetes Treatment Drugs Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal GLP-1 Diabetes Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Diabetes Treatment Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Diabetes Treatment Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global GLP-1 Diabetes Treatment Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for GLP-1 Diabetes Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for GLP-1 Diabetes Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GLP-1 Diabetes Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of GLP-1 Diabetes Treatment Drugs include Tonghua Dongbao, Shanghai Renhui Biopharmaceuticals Co., Ltd., Sanofi, Page Biopharmaceuticals, Novo Nordisk, Eli Lilly, Jiangsu Hausen Pharmaceuticals Group Co., Ltd., Huadong Medicine and Ganli Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global GLP-1 Diabetes Treatment Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The GLP-1 Diabetes Treatment Drugs market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global GLP-1 Diabetes Treatment Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to GLP-1 Diabetes Treatment Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global GLP-1 Diabetes Treatment Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

GLP-1 Diabetes Treatment Drugs Market by Company

Tonghua Dongbao

Shanghai Renhui Biopharmaceuticals Co., Ltd.

Sanofi

Page Biopharmaceuticals

Novo Nordisk

Eli Lilly

Jiangsu Hausen Pharmaceuticals Group Co., Ltd.

Huadong Medicine

Ganli Pharmaceuticals

AstraZeneca

Teva Pharmaceutical Industries Ltd

Pfizer Inc

Hanmi Pharmaceutical Co

GlaxoSmithKline (GSK)

Boehringer Ingelheim

GLP-1 Diabetes Treatment Drugs Segment by Type

Exenatide

Dulaglutide

Laglutide

Others

GLP-1 Diabetes Treatment Drugs Segment by Application

Online Pharmacy

Hospital

Clinic

GLP-1 Diabetes Treatment Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Diabetes Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Diabetes Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Diabetes Treatment Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of GLP-1 Diabetes Treatment Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of GLP-1 Diabetes Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Exenatide Table 2. Major Company of Dulaglutide Table 3. Major Company of Laglutide Table 4. Major Company of Others Table 5. Global GLP-1 Diabetes Treatment Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (k units) Table 7. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Type (2021-2026) Table 8. Global GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 9. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Type (2021-2026) Table 10. Global GLP-1 Diabetes Treatment Drugs Price by Type (2021-2026) & (USD/unit) Table 11. Global GLP-1 Diabetes Treatment Drugs Sales by Type (2027-2032) & (k units) Table 12. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Type (2027-2032) Table 13. Global GLP-1 Diabetes Treatment Drugs Sales by Type (2027-2032) & (US$ Million) Table 14. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Type (2027-2032) Table 15. Global GLP-1 Diabetes Treatment Drugs Price by Type (2027-2032) & (USD/unit) Table 16. North America GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (k units) Table 17. North America GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Europe GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (k units) Table 19. Europe GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (k units) Table 23. Latin America GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. GLP-1 Diabetes Treatment Drugs Industry Trends Table 27. GLP-1 Diabetes Treatment Drugs Industry Drivers Table 28. GLP-1 Diabetes Treatment Drugs Industry Opportunities and Challenges Table 29. GLP-1 Diabetes Treatment Drugs Industry Restraints Table 30. Global GLP-1 Diabetes Treatment Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global GLP-1 Diabetes Treatment Drugs Revenue Market Share by Company (2021-2026) Table 32. Global GLP-1 Diabetes Treatment Drugs Sales by Company (2021-2026) & (k units) Table 33. Global GLP-1 Diabetes Treatment Drugs Sales Share by Company (2021-2026) Table 34. Global GLP-1 Diabetes Treatment Drugs Market Price by Company (2021-2026) & (USD/unit) Table 35. Global GLP-1 Diabetes Treatment Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global GLP-1 Diabetes Treatment Drugs Major Company Production Sites and Headquarters Table 37. Global GLP-1 Diabetes Treatment Drugs Company, Product Type & Application Table 38. Global GLP-1 Diabetes Treatment Drugs Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global GLP-1 Diabetes Treatment Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global GLP-1 Diabetes Treatment Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global GLP-1 Diabetes Treatment Drugs Sales by Region (2021-2026) & (k units) Table 43. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Region (2021-2026) Table 44. Global GLP-1 Diabetes Treatment Drugs Sales by Region (2021-2026) & (US$ Million) Table 45. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Region (2021-2026) Table 46. Global GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 47. Global GLP-1 Diabetes Treatment Drugs Sales by Region (2027-2032) & (k units) Table 48. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Region (2027-2032) Table 49. Global GLP-1 Diabetes Treatment Drugs Sales by Region (2027-2032) & (US$ Million) Table 50. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Region (2027-2032) Table 51. Global GLP-1 Diabetes Treatment Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2027-2032) Table 52. Global GLP-1 Diabetes Treatment Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (k units) Table 54. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Application (2021-2026) Table 55. Global GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 56. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Application (2021-2026) Table 57. Global GLP-1 Diabetes Treatment Drugs Price by Application (2021-2026) & (USD/unit) Table 58. Global GLP-1 Diabetes Treatment Drugs Sales by Application (2027-2032) & (k units) Table 59. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Application (2027-2032) Table 60. Global GLP-1 Diabetes Treatment Drugs Sales by Application (2027-2032) & (US$ Million) Table 61. Global GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Application (2027-2032) Table 62. Global GLP-1 Diabetes Treatment Drugs Price by Application (2027-2032) & (USD/unit) Table 63. North America GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (k units) Table 64. North America GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Europe GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (k units) Table 66. Europe GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (k units) Table 70. Latin America GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Tonghua Dongbao Company Information Table 74. Tonghua Dongbao Business Overview Table 75. Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Product Portfolio Table 77. Tonghua Dongbao Recent Development Table 78. Shanghai Renhui Biopharmaceuticals Co., Ltd. Company Information Table 79. Shanghai Renhui Biopharmaceuticals Co., Ltd. Business Overview Table 80. Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio Table 82. Shanghai Renhui Biopharmaceuticals Co., Ltd. Recent Development Table 83. Sanofi Company Information Table 84. Sanofi Business Overview Table 85. Sanofi GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Sanofi GLP-1 Diabetes Treatment Drugs Product Portfolio Table 87. Sanofi Recent Development Table 88. Page Biopharmaceuticals Company Information Table 89. Page Biopharmaceuticals Business Overview Table 90. Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio Table 92. Page Biopharmaceuticals Recent Development Table 93. Novo Nordisk Company Information Table 94. Novo Nordisk Business Overview Table 95. Novo Nordisk GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Novo Nordisk GLP-1 Diabetes Treatment Drugs Product Portfolio Table 97. Novo Nordisk Recent Development Table 98. Eli Lilly Company Information Table 99. Eli Lilly Business Overview Table 100. Eli Lilly GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Eli Lilly GLP-1 Diabetes Treatment Drugs Product Portfolio Table 102. Eli Lilly Recent Development Table 103. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Company Information Table 104. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Business Overview Table 105. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio Table 107. Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Recent Development Table 108. Huadong Medicine Company Information Table 109. Huadong Medicine Business Overview Table 110. Huadong Medicine GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Huadong Medicine GLP-1 Diabetes Treatment Drugs Product Portfolio Table 112. Huadong Medicine Recent Development Table 113. Ganli Pharmaceuticals Company Information Table 114. Ganli Pharmaceuticals Business Overview Table 115. Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio Table 117. Ganli Pharmaceuticals Recent Development Table 118. AstraZeneca Company Information Table 119. AstraZeneca Business Overview Table 120. AstraZeneca GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. AstraZeneca GLP-1 Diabetes Treatment Drugs Product Portfolio Table 122. AstraZeneca Recent Development Table 123. Teva Pharmaceutical Industries Ltd Company Information Table 124. Teva Pharmaceutical Industries Ltd Business Overview Table 125. Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Product Portfolio Table 127. Teva Pharmaceutical Industries Ltd Recent Development Table 128. Pfizer Inc Company Information Table 129. Pfizer Inc Business Overview Table 130. Pfizer Inc GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Pfizer Inc GLP-1 Diabetes Treatment Drugs Product Portfolio Table 132. Pfizer Inc Recent Development Table 133. Hanmi Pharmaceutical Co Company Information Table 134. Hanmi Pharmaceutical Co Business Overview Table 135. Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Product Portfolio Table 137. Hanmi Pharmaceutical Co Recent Development Table 138. GlaxoSmithKline (GSK) Company Information Table 139. GlaxoSmithKline (GSK) Business Overview Table 140. GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Product Portfolio Table 142. GlaxoSmithKline (GSK) Recent Development Table 143. Boehringer Ingelheim Company Information Table 144. Boehringer Ingelheim Business Overview Table 145. Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Product Portfolio Table 147. Boehringer Ingelheim Recent Development Table 148. North America GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 149. North America GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026) & (k units) Table 150. North America GLP-1 Diabetes Treatment Drugs Sales Market Share by Country (2021-2026) Table 151. North America GLP-1 Diabetes Treatment Drugs Sales Forecast by Country (2027-2032) & (k units) Table 152. North America GLP-1 Diabetes Treatment Drugs Sales Market Share Forecast by Country (2027-2032) Table 153. North America GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. North America GLP-1 Diabetes Treatment Drugs Market Size by Country (2021-2026) & (US$ Million) Table 155. North America GLP-1 Diabetes Treatment Drugs Market Share by Country (2021-2026) Table 156. North America GLP-1 Diabetes Treatment Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. North America GLP-1 Diabetes Treatment Drugs Market Share Forecast by Country (2027-2032) Table 158. Europe GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 159. Europe GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026) & (k units) Table 160. Europe GLP-1 Diabetes Treatment Drugs Sales Market Share by Country (2021-2026) Table 161. Europe GLP-1 Diabetes Treatment Drugs Sales Forecast by Country (2027-2032) & (k units) Table 162. Europe GLP-1 Diabetes Treatment Drugs Sales Market Share Forecast by Country (2027-2032) Table 163. Europe GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Europe GLP-1 Diabetes Treatment Drugs Market Size by Country (2021-2026) & (US$ Million) Table 165. Europe GLP-1 Diabetes Treatment Drugs Market Share by Country (2021-2026) Table 166. Europe GLP-1 Diabetes Treatment Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Europe GLP-1 Diabetes Treatment Drugs Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026) & (k units) Table 170. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Market Share by Country (2021-2026) Table 171. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Forecast by Country (2027-2032) & (k units) Table 172. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Size by Country (2021-2026) & (US$ Million) Table 175. Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Share by Country (2021-2026) Table 176. Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Share Forecast by Country (2027-2032) Table 178. Latin America GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 179. Latin America GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026) & (k units) Table 180. Latin America GLP-1 Diabetes Treatment Drugs Sales Market Share by Country (2021-2026) Table 181. Latin America GLP-1 Diabetes Treatment Drugs Sales Forecast by Country (2027-2032) & (k units) Table 182. Latin America GLP-1 Diabetes Treatment Drugs Sales Market Share Forecast by Country (2027-2032) Table 183. Latin America GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. Latin America GLP-1 Diabetes Treatment Drugs Market Size by Country (2021-2026) & (US$ Million) Table 185. Latin America GLP-1 Diabetes Treatment Drugs Market Share by Country (2021-2026) Table 186. Latin America GLP-1 Diabetes Treatment Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. Latin America GLP-1 Diabetes Treatment Drugs Market Share Forecast by Country (2027-2032) Table 188. Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 189. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026) & (k units) Table 190. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Market Share by Country (2021-2026) Table 191. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Forecast by Country (2027-2032) & (k units) Table 192. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Market Share Forecast by Country (2027-2032) Table 193. Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 194. Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Size by Country (2021-2026) & (US$ Million) Table 195. Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Share by Country (2021-2026) Table 196. Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Share Forecast by Country (2027-2032) Table 198. Key Raw Materials Table 199. Raw Materials Key Suppliers Table 200. GLP-1 Diabetes Treatment Drugs Distributors List Table 201. GLP-1 Diabetes Treatment Drugs Customers List Table 202. Research Programs/Design for This Report Table 203. Authors List of This Report Table 204. Secondary Sources Table 205. Primary Sources List of Figures Figure 1. GLP-1 Diabetes Treatment Drugs Image Figure 2. Global GLP-1 Diabetes Treatment Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Diabetes Treatment Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Diabetes Treatment Drugs Sales (2021-2032) & (k units) Figure 5. Exenatide Image Figure 6. Global Exenatide Sales YoY Growth (2021-2032) & (k units) Figure 7. Dulaglutide Image Figure 8. Global Dulaglutide Sales YoY Growth (2021-2032) & (k units) Figure 9. Laglutide Image Figure 10. Global Laglutide Sales YoY Growth (2021-2032) & (k units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 13. Global GLP-1 Diabetes Treatment Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global GLP-1 Diabetes Treatment Drugs Market Share by Type 2025 VS 2032 Figure 15. North America GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Type in 2025 Figure 16. North America GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Type in 2025 Figure 17. Europe GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Europe GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Type in 2025 Figure 21. Latin America GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Latin America GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 GLP-1 Diabetes Treatment Drugs Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Online Pharmacy Image Figure 28. Global Online Pharmacy Sales YoY Growth (2021-2032) & (k units) Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 33. Global GLP-1 Diabetes Treatment Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global GLP-1 Diabetes Treatment Drugs Market Share by Application 2025 VS 2032 Figure 35. North America GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Application in 2025 Figure 36. North America GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Application in 2025 Figure 37. Europe GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Europe GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Application in 2025 Figure 41. Latin America GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Latin America GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Market Share in Value by Application in 2025 Figure 45. North America GLP-1 Diabetes Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America GLP-1 Diabetes Treatment Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America GLP-1 Diabetes Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America GLP-1 Diabetes Treatment Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe GLP-1 Diabetes Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe GLP-1 Diabetes Treatment Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe GLP-1 Diabetes Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe GLP-1 Diabetes Treatment Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America GLP-1 Diabetes Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America GLP-1 Diabetes Treatment Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America GLP-1 Diabetes Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America GLP-1 Diabetes Treatment Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. GLP-1 Diabetes Treatment Drugs Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. GLP-1 Diabetes Treatment Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Exenatide
  • Dulaglutide
  • Laglutide
  • Others
Applications
  • Online Pharmacy
  • Hospital
  • Clinic
Companies covered
  • Tonghua Dongbao
  • Shanghai Renhui Biopharmaceuticals Co., Ltd.
  • Sanofi
  • Page Biopharmaceuticals
  • Novo Nordisk
  • Eli Lilly
  • Jiangsu Hausen Pharmaceuticals Group Co., Ltd.
  • Huadong Medicine
  • Ganli Pharmaceuticals
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Hanmi Pharmaceutical Co
  • GlaxoSmithKline (GSK)
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GLP-1 Diabetes Treatment Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global GLP-1 Diabetes Treatment Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 GLP-1 Diabetes Treatment Drugs Market by Type
  6. 1.3.1 Exenatide
  7. 1.3.2 Dulaglutide
  8. 1.3.3 Laglutide
  9. 1.3.4 Others
  10. 1.4 Global GLP-1 Diabetes Treatment Drugs Market Size by Type
  11. 1.4.1 Global GLP-1 Diabetes Treatment Drugs Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global GLP-1 Diabetes Treatment Drugs Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global GLP-1 Diabetes Treatment Drugs Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America GLP-1 Diabetes Treatment Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe GLP-1 Diabetes Treatment Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America GLP-1 Diabetes Treatment Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 GLP-1 Diabetes Treatment Drugs Industry Trends
  2. 2.2 GLP-1 Diabetes Treatment Drugs Industry Drivers
  3. 2.3 GLP-1 Diabetes Treatment Drugs Industry Opportunities and Challenges
  4. 2.4 GLP-1 Diabetes Treatment Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by GLP-1 Diabetes Treatment Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by GLP-1 Diabetes Treatment Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by GLP-1 Diabetes Treatment Drugs Price (2021-2026)
  4. 3.4 Global GLP-1 Diabetes Treatment Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global GLP-1 Diabetes Treatment Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global GLP-1 Diabetes Treatment Drugs Company, Product Type & Application
  7. 3.7 Global GLP-1 Diabetes Treatment Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global GLP-1 Diabetes Treatment Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 GLP-1 Diabetes Treatment Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 GLP-1 Diabetes Treatment Drugs Tier 1, Tier 2, and Tier 3
4 GLP-1 Diabetes Treatment Drugs Regional Status and Outlook
  1. 4.1 Global GLP-1 Diabetes Treatment Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global GLP-1 Diabetes Treatment Drugs Historic Market Size by Region
  3. 4.2.1 Global GLP-1 Diabetes Treatment Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global GLP-1 Diabetes Treatment Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global GLP-1 Diabetes Treatment Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global GLP-1 Diabetes Treatment Drugs Forecasted Market Size by Region
  7. 4.3.1 Global GLP-1 Diabetes Treatment Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global GLP-1 Diabetes Treatment Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global GLP-1 Diabetes Treatment Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 GLP-1 Diabetes Treatment Drugs by Application
  1. 5.1 GLP-1 Diabetes Treatment Drugs Market by Application
  2. 5.1.1 Online Pharmacy
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.2 Global GLP-1 Diabetes Treatment Drugs Market Size by Application
  6. 5.2.1 Global GLP-1 Diabetes Treatment Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global GLP-1 Diabetes Treatment Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global GLP-1 Diabetes Treatment Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America GLP-1 Diabetes Treatment Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe GLP-1 Diabetes Treatment Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America GLP-1 Diabetes Treatment Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Tonghua Dongbao
  2. 6.1.1 Tonghua Dongbao Company Information
  3. 6.1.2 Tonghua Dongbao Business Overview
  4. 6.1.3 Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Tonghua Dongbao GLP-1 Diabetes Treatment Drugs Product Portfolio
  6. 6.1.5 Tonghua Dongbao Recent Developments
  7. 6.2 Shanghai Renhui Biopharmaceuticals Co., Ltd.
  8. 6.2.1 Shanghai Renhui Biopharmaceuticals Co., Ltd. Company Information
  9. 6.2.2 Shanghai Renhui Biopharmaceuticals Co., Ltd. Business Overview
  10. 6.2.3 Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Shanghai Renhui Biopharmaceuticals Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio
  12. 6.2.5 Shanghai Renhui Biopharmaceuticals Co., Ltd. Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Sanofi GLP-1 Diabetes Treatment Drugs Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 Page Biopharmaceuticals
  20. 6.4.1 Page Biopharmaceuticals Company Information
  21. 6.4.2 Page Biopharmaceuticals Business Overview
  22. 6.4.3 Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Page Biopharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio
  24. 6.4.5 Page Biopharmaceuticals Recent Developments
  25. 6.5 Novo Nordisk
  26. 6.5.1 Novo Nordisk Company Information
  27. 6.5.2 Novo Nordisk Business Overview
  28. 6.5.3 Novo Nordisk GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Novo Nordisk GLP-1 Diabetes Treatment Drugs Product Portfolio
  30. 6.5.5 Novo Nordisk Recent Developments
  31. 6.6 Eli Lilly
  32. 6.6.1 Eli Lilly Company Information
  33. 6.6.2 Eli Lilly Business Overview
  34. 6.6.3 Eli Lilly GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Eli Lilly GLP-1 Diabetes Treatment Drugs Product Portfolio
  36. 6.6.5 Eli Lilly Recent Developments
  37. 6.7 Jiangsu Hausen Pharmaceuticals Group Co., Ltd.
  38. 6.7.1 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Company Information
  39. 6.7.2 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Business Overview
  40. 6.7.3 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. GLP-1 Diabetes Treatment Drugs Product Portfolio
  42. 6.7.5 Jiangsu Hausen Pharmaceuticals Group Co., Ltd. Recent Developments
  43. 6.8 Huadong Medicine
  44. 6.8.1 Huadong Medicine Company Information
  45. 6.8.2 Huadong Medicine Business Overview
  46. 6.8.3 Huadong Medicine GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Huadong Medicine GLP-1 Diabetes Treatment Drugs Product Portfolio
  48. 6.8.5 Huadong Medicine Recent Developments
  49. 6.9 Ganli Pharmaceuticals
  50. 6.9.1 Ganli Pharmaceuticals Company Information
  51. 6.9.2 Ganli Pharmaceuticals Business Overview
  52. 6.9.3 Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Ganli Pharmaceuticals GLP-1 Diabetes Treatment Drugs Product Portfolio
  54. 6.9.5 Ganli Pharmaceuticals Recent Developments
  55. 6.10 AstraZeneca
  56. 6.10.1 AstraZeneca Company Information
  57. 6.10.2 AstraZeneca Business Overview
  58. 6.10.3 AstraZeneca GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 AstraZeneca GLP-1 Diabetes Treatment Drugs Product Portfolio
  60. 6.10.5 AstraZeneca Recent Developments
  61. 6.11 Teva Pharmaceutical Industries Ltd
  62. 6.11.1 Teva Pharmaceutical Industries Ltd Company Information
  63. 6.11.2 Teva Pharmaceutical Industries Ltd Business Overview
  64. 6.11.3 Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Teva Pharmaceutical Industries Ltd GLP-1 Diabetes Treatment Drugs Product Portfolio
  66. 6.11.5 Teva Pharmaceutical Industries Ltd Recent Developments
  67. 6.12 Pfizer Inc
  68. 6.12.1 Pfizer Inc Company Information
  69. 6.12.2 Pfizer Inc Business Overview
  70. 6.12.3 Pfizer Inc GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Pfizer Inc GLP-1 Diabetes Treatment Drugs Product Portfolio
  72. 6.12.5 Pfizer Inc Recent Developments
  73. 6.13 Hanmi Pharmaceutical Co
  74. 6.13.1 Hanmi Pharmaceutical Co Company Information
  75. 6.13.2 Hanmi Pharmaceutical Co Business Overview
  76. 6.13.3 Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Hanmi Pharmaceutical Co GLP-1 Diabetes Treatment Drugs Product Portfolio
  78. 6.13.5 Hanmi Pharmaceutical Co Recent Developments
  79. 6.14 GlaxoSmithKline (GSK)
  80. 6.14.1 GlaxoSmithKline (GSK) Company Information
  81. 6.14.2 GlaxoSmithKline (GSK) Business Overview
  82. 6.14.3 GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 GlaxoSmithKline (GSK) GLP-1 Diabetes Treatment Drugs Product Portfolio
  84. 6.14.5 GlaxoSmithKline (GSK) Recent Developments
  85. 6.15 Boehringer Ingelheim
  86. 6.15.1 Boehringer Ingelheim Company Information
  87. 6.15.2 Boehringer Ingelheim Business Overview
  88. 6.15.3 Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Boehringer Ingelheim GLP-1 Diabetes Treatment Drugs Product Portfolio
  90. 6.15.5 Boehringer Ingelheim Recent Developments
7 North America by Country
  1. 7.1 North America GLP-1 Diabetes Treatment Drugs Sales by Country
  2. 7.1.1 North America GLP-1 Diabetes Treatment Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America GLP-1 Diabetes Treatment Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America GLP-1 Diabetes Treatment Drugs Market Size by Country
  6. 7.2.1 North America GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America GLP-1 Diabetes Treatment Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America GLP-1 Diabetes Treatment Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe GLP-1 Diabetes Treatment Drugs Sales by Country
  2. 8.1.1 Europe GLP-1 Diabetes Treatment Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe GLP-1 Diabetes Treatment Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe GLP-1 Diabetes Treatment Drugs Market Size by Country
  6. 8.2.1 Europe GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe GLP-1 Diabetes Treatment Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe GLP-1 Diabetes Treatment Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales by Country
  2. 9.1.1 Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific GLP-1 Diabetes Treatment Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific GLP-1 Diabetes Treatment Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America GLP-1 Diabetes Treatment Drugs Sales by Country
  2. 10.1.1 South America GLP-1 Diabetes Treatment Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America GLP-1 Diabetes Treatment Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America GLP-1 Diabetes Treatment Drugs Market Size by Country
  6. 10.2.1 South America GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America GLP-1 Diabetes Treatment Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America GLP-1 Diabetes Treatment Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales by Country
  2. 11.1.1 Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa GLP-1 Diabetes Treatment Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa GLP-1 Diabetes Treatment Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 GLP-1 Diabetes Treatment Drugs Value Chain Analysis
  2. 12.1.1 GLP-1 Diabetes Treatment Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 GLP-1 Diabetes Treatment Drugs Production Mode & Process
  7. 12.2 GLP-1 Diabetes Treatment Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 GLP-1 Diabetes Treatment Drugs Distributors
  10. 12.2.3 GLP-1 Diabetes Treatment Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst